An observational study in Chronic Kidney Disease, sponsored by Pharmicell Co., Ltd.. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Pharmicell Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of — 18 open to participants now, 30 under way, 17 of them phase 3. Renal Insufficiency, Chronic · Korea, Republic of.
Among the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, this one is the 23rd largest by enrollment of the 23 observational ones that give a count, is one of 12 that started in 2022, is one of 23 observational ones, reaches primary completion later than 9 of the 29 other live ones, and was the 79th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →18 of the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Korea, Republic of, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, China and 5 more countries
Ages 2–18
Chungnam National University Hospital · Sites in Korea, Republic of
Ages 19–84
Eli Lilly and Company · Sites in Korea, Republic of, Argentina, Australia and 35 more countries
Ages 50+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 19 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 52 · Phase 4 20
First in 2003; this study’s year is marked. 12 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 213 across 835 observational studies indexed under Renal Insufficiency, Chronic.
Median enrollment 351 across the 101 interventional studies, 748 across the 23 observational. Of the 79 that completed or were terminated, 38 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 124 have an industry lead sponsor. The 10 most frequent:
Pharmicell Co., Ltd. is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Pharmicell Co., Ltd. has 2 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
9 of the studies in Renal Insufficiency, Chronic with a site in Korea, Republic of that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07231679Ingenia Therapeutics INCA Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney Disease | 2026-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 124 studies in Renal Insufficiency, Chronic with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov. Identifier: NCT05042206).
This long-term follow-up study is a 5-year long-term follow-up study to evaluate long-term safety in Cellgram-CKD subjects. (refer to ClinicalTrials.gov.Identifier: NCT05042206).
The long-term safety of Cellgram-CKD is evaluated by monitoring whether or not an adverse event of special interest (AESI) occurs for 5 years from the date of administration in Cellgram-CKD subjects who voluntarily consented in writing to participate in the long-term follow-up study.
Patients with chronic kidney disease who participated in the PMC-P-12 clinical trial, among those who received Cellgram-CKD, those who agreed to participate in this long-term follow-up study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Observe the occurrence of Adverse Event of Special Interest (AESI).
AESI stands for Serious Adverse Event as follows. 1. death 2. Creation of neoplasms or malignancies in tissues or organs 3. The development of an immune response, including the exacerbation or new development of a previous autoimmune disease 4. Occurrence of Other delayed adverse events related to stem cell therapy
Time frame: 5 years from the date of administration of Cellgram-CKD
Started Mar 2022 (actual). Primary completion is estimated for Mar 2027, 60 months after the start.
Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 60 months is above that.
Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →
Pharmicell Co., Ltd.